

WHAT IS CLAIMED IS:

1. An anti-microbial composition comprising a therapeutically effective amount of at least one anti-microbial neutralizing antibody, including
5 therapeutically active variants and fragments thereof, and at least one anti-inflammatory agent wherein said neutralizing antibody and said anti-inflammatory agent are suspended in a pharmacologically acceptable carrier.

2. The anti-microbial composition of claim 1 wherein said antibody is
10 an anti-viral antibody.

3. The composition of claim 1 wherein said composition comprises at least 2 anti-microbial antibodies, including therapeutically active variants and fragments thereof.
15

4. The anti-microbial composition of claim 1 wherein said neutralizing antibody has affinity for the F epitope of respiratory syncytial virus.

5. The anti-microbial composition of claim 1 wherein said composition
20 comprises at least 2 anti-microbial neutralizing antibodies of differing specificity, including therapeutically active variants and fragments thereof.

6. The anti-microbial composition of claim 5 wherein said anti-microbial neutralizing antibodies comprise at least one anti-viral antibody and
25 at least one antibody with specificity for an epitope found on a non-viral microbe.

7. The anti-microbial composition of claim 5 wherein said anti-microbial neutralizing antibodies are selected from the group consisting of
30 antiviral, antibacterial, anti-fungal, and anti-parasitic antibodies.

8. The composition of claim 1 wherein said anti-inflammatory agent is an antibody.

9. The composition of claim 8 wherein said antibody is selected from the group consisting of an anti-cytokine, anti-chemokine, anti-interleukin antibody, an anti-interferon antibody, and an anti-tumor necrosis factor antibody.

10. The composition of claim 8 wherein said antibody is anti-interleukin-6.

11. The composition of claim 1 wherein said anti-inflammatory agent is a steroid.

12. The composition of claim 11 wherein said steroid is a corticosteroid,.

13. The composition of claim 12 wherein the corticosteroid is selected from the group consisting of cortisone, hydrocortisone, prednisone, prednisolone, methylprednisolone, triamcinolone, betamethasone, beclamethasone and dexamethasone.

14. The composition of claim 1 wherein said at least one anti-inflammatory agent is a combination of triamcinolone and methylprednisolone.

15. The composition of claim 1 wherein the anti-inflammatory agent is selected from the group consisting of ibuprofen, indomethacin, acetylsalicylic acid and acetaminophen.

16. A composition comprising a therapeutically effective amount of at least one anti-respiratory syncytial virus (anti-RSV) antibody, including therapeutically active variants and fragments thereof, at least one additional anti-microbial agent, and at least one anti-inflammatory agent wherein said anti-RSV antibody, said additional anti-infectious agent, and said anti-inflammatory agent are suspended in a pharmacologically acceptable carrier, diluent or excipient.

17. The composition of claim 16 wherein said additional anti-microbial agent is an anti-viral agent and said anti-inflammatory agent is a corticosteroid.

18. The composition of claim 17 wherein said anti-viral agent is ribavirin, amantadine, rimantadine, or a neuraminidase-inhibitor.

19. The composition of claim 16 wherein said additional anti-microbial agent is an anti-bacterial agent.

20. The composition of claim 16 wherein said additional anti-microbial agent is an anti-fungal agent.

21. The composition of claim 16 wherein said additional anti-microbial agent is an anti-parasitic agent.

22. A method of treating a respiratory disease in a patient afflicted therewith comprising the administering to said patient a therapeutically effective amount of a composition of claim 1.

23. The method of claim 22 wherein said disease is selected from the group consisting of respiratory syncytial disease, bronchiolitis, or influenza.

24. The method of claim 22 wherein said antibody is Medi-493 (or palivizumab).

5 25. A method of protecting against a respiratory disease in a patient at risk thereof comprising administering to said patient a therapeutically effective amount of a composition of claim 1.

10 26. The method of claim 25 wherein said disease is selected from the group consisting of respiratory syncytial disease, bronchiolitis, or influenza.

15 27. The method of claim 25 wherein said antibody is Medi-493 (or palivizumab).

20

25

30

35